1 option
CADTH reimbursement recommendation Pembrolizumab (Keytruda) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Series:
- CADTH drug reimbursement review.
- CADTH drug reimbursement review
- Language:
- English
- Subjects (All):
- Cost effectiveness.
- Physical Description:
- 1 online resource (19 pages).
- Place of Publication:
- Ottawa : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of esophageal or human epidermal growth factor receptor 2 (HER2)-negative esophagogastric junction (EGJ) cancer that cannot be removed by surgery or is metastatic, if certain conditions are met.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.